Gastroesophageal Reflux Disease (GERD) Market Growth Outlook Through 2024-2033

Overview and Scope
Gastroesophageal reflux disease (GERD) is a condition in which stomach acid flows back into the esophagus, causing irritation and discomfort. The treatment for the disease includes various medical strategies and interventions employed to manage the symptoms and complications associated with gastroesophageal reflux disease.

Sizing and Forecast
The gastroesophageal reflux disease (gerd) market size has grown marginally in recent years. It will grow from $5.15 billion in 2023 to $5.25 billion in 2024 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to lifestyle and dietary changes, obesity epidemic, growing awareness about gerd treatment, globalization of pharmaceutical industry, investments for gerd treatments.

The gastroesophageal reflux disease (gerd) market size is expected to see steady growth in the next few years. It will grow to $5.74 billion in 2028 at a compound annual growth rate (CAGR) of 2.3%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, emergence of biomarker, growing number of screening programs for gerd, increasing prevalence of heartburn, increased demand for medical equipment. Major trends in the forecast period include diagnostic advancements, surgical advancements, development of targeted therapies, adoption of telehealth services .

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-gerd-global-market-report

Segmentation & Regional Insights
The gastroesophageal reflux disease (gerd) market covered in this report is segmented –

1) By Drug Type: Antacids; Proton Pump Inhibitors; H2 Receptor Blocker; Pro Kinetic Agents; Dopamine Receptor Antagonist; EndoCinch; Stretta; EsophyX; Transoral Incisionless Fundoplication (TIF)
2) By Procedure: Invasive; Minimally Invasive
3) By End-Users: Hospital; Homecare; Specialty Clinics

North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12917&type=smp

Major Driver Impacting Market Growth
The growing prevalence of esophageal diseases is expected to propel the growth of the gastroesophageal reflux disease (GERD) market going forward. Esophageal diseases are medical conditions that affect the esophagus, a muscular tube connecting the mouth to the stomach. The treatment of esophageal diseases aims to alleviate symptoms, improve quality of life and prevent complications, ultimately promoting better overall health and well-being for gastroesophageal reflux disease-affected individuals. For instance, in January 2023, according to the American Cancer Society, a US-based Professional organization, about 21,560 new esophageal cancer cases are diagnosed yearly in the United States, with 16,120 deaths from esophageal cancer. Therefore, the growing prevalence of esophageal diseases drives the growth of the gastroesophageal reflux disease (GERD) market.

Key Industry Players
Major players in the gastroesophageal reflux disease (gerd) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.

The gastroesophageal reflux disease (gerd) market report table of contents includes:

1. Executive Summary
2.Gastroesophageal Reflux Disease (GERD) Market Characteristics
3.Gastroesophageal Reflux Disease (GERD) Market Trends And Strategies
4.Gastroesophageal Reflux Disease (GERD)  Market analysis
5. Gastroesophageal Reflux Disease (GERD)Market Size And Growth
6. Gastroesophageal Reflux Disease (GERD)Segmentation
7.Gastroesophageal Reflux Disease (GERD) Regional And Country Analysis
.
.
.
27. Gastroesophageal Reflux Disease (GERD)Competitive Landscape And Company Profiles
28.Gastroesophageal Reflux Disease (GERD) Key Mergers And Acquisitions
29.Gastroesophageal Reflux Disease (GERD) Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• GlaxoSmithKline PLC
• SRS Life Sciences
• Johnson & Johnson Services Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca PLC

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model